Ypsomed takeover of Florian Müller Holding GmbH boosts diabetes direct business in Germany

Press Releases Ypsomed Group

Burgdorf - With effect from 1 July 2007 and at a cost of around EUR 11 million (approx. CHF 18 million), Ypsomed has bought 100% of the shares in Florian Müller Holding GmbH, thus providing nationwide coverage in diabetes direct sales and distribution throughout Germany, with the focus on the care of insulin pump patients.

En savoir plus...

Ypsomed has a firm commitment to the region. From 27 June 2007 its shares will – in addition to the SWX – be listed on the Berne Exchange

Press Releases Ypsomed Group

Burgdorf - Ypsomed Holding AGr ecently applied for a listing on the BX Berne eXchange in addition to the present listing on the SWX Swiss Exchange. The Berne Stock Market Association as the BX Berne eXchange operator has accepted this application. All the registered shares of Ypsomed Holding AG will therefore also be listed on the BX Berne eXchange from 27 June 2007.

En savoir plus...

Ypsomed and Adval Tech agree a strategic cooperation in moldmaking

Press Releases Ypsomed Group

Burgdorf - Ypsomed AG, Burgdorf, and Adval Tech Holding Ltd, Niederwangen, have signed an agreement on a strategic cooperation in moldmaking. The goal of this agreement is to combine the respective strengths and core competencies of Ypsomed and Adval Tech and exploit them for the economical manufacturing of highquality medtec products.

En savoir plus...

Ypsomed 2006/07 business year

Press Releases Ypsomed Group

Burgdorf - In business year 2006/07 the Ypsomed Group posted consolidated sales of CHF 277.5 million (-10.7% prior year), returning to profitability as announced in the second half of the year with consolidated net profits of CHF 2.7 million.

En savoir plus...

Ypsomed concludes License Agreement on own auto-injector patents with major pharmaceutical company

Press Releases Ypsomed Group

Burgdorf - Ypsomed is pleased to announce that it has granted to a major, globally acting pharmaceutical company a non exclusive license to use certain patents, which protect inventions of Ypsomed in the area of auto-injector technology. Ypsomed expects to receive several million Swiss Francs in license fees over the term of the concluded agreement.

En savoir plus...